
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.67057
Neurology
Psychiatry
Infectious Disease
Lyme Neuroborreliosis in the Context of Dementia Syndromes
Muacevic Alexander
Adler John R
Bashchobanov Dzhaner H 1
Stamatova Eva 1
Andonova Radina 2
Dragusheva Elena 2
Gadzhovska Veronika 2
Popov Georgi 2
1 Medicine, Medical University of Sofia, Sofia, BGR
2 Infectious Diseases, Sofiamed, Sofia, BGR
Dzhaner H. Bashchobanov dzhaner456@icloud.com
17 8 2024
8 2024
16 8 e6705717 8 2024
Copyright © 2024, Bashchobanov et al.
2024
Bashchobanov et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/276245-lyme-neuroborreliosis-in-the-context-of-dementia-syndromes
Lyme disease (LD) can affect the skin, joints, heart, and nervous system as a multisystemic condition. The cause of the illness is the spirochete of the genus Borrelia. These pathogens can affect the skin, joints, heart, and nervous system. Lyme neuroborreliosis (LNB) is the term for the disease, which occurs when the nervous system gets involved. Regarding geographical distribution, LNB is more prevalent in Europe than in North America. The most significant change in pathogenesis is inflammation of the central nervous system (CNS) and peripheral nervous system (PNS). Furthermore, clinically, it can represent a variety of neurological manifestations, such as meningitis, encephalitis, radiculopathies, and cranial neuritis. However, dementia-like syndrome is an infrequent manifestation of Lyme disease. Our review article aims to summarize the similarities and differences between dementia-like syndrome in LNB and that in primary neurodegenerative diseases, as well as to look for a correlation between the pathogenesis of the disease and the possibility of developing dementia-like syndrome. The world literature lacks sufficiently convincing data on the relationship between spirochete infection and primary dementia syndromes. However, cases of secondary dementia syndrome due to nervous system involvement as well as post-treatment have been described. A thorough examination, medical history, laboratory and imaging studies, cerebrospinal fluid (CSF) examination, MRI, and fludeoxyglucose-18-positron emission tomography (FGD-PET) are required to differentiate between these syndromes.

microbial pathogenesis
nervous system lyme disease
alzheimer's disease
dementia syndromes
lyme neuroborreliosis
lyme disease
==== Body
pmcIntroduction and background

Lyme disease (LD) is the leading tick-borne illness in the Northern Hemisphere. Its causative agent is a spirochete of the genus Borrelia (B. burgdorferi (Bb), B. garinii, and B. afzelii) [1]. The vector of transmission is the tick Ixodes spp. [1]. The LD bacterium, named after its discoverer Wilhelm Burgdorfer in 1982, was first reported in Lyme, Connecticut, USA [2, 3].

Lyme disease is a multisystem disorder demonstrating fever, headache, joint pain, muscle weakness, fatigue, and a typical skin rash. When the skin is involved, it can represent three forms: erythema migrans (EM), borrelial lymphocytoma (BL), and acrodermatitis chronica atrophicans (ACA) [4]. Other typical manifestations involve joints (Lyme arthritis), the heart (Lyme carditis), and the neurological system (Lyme neuroborreliosis (LNB)) [5].

In the context of the epidemiological distribution of the Borrelia species, a broad difference may explain the discrepancy in the clinical course of LD in distinct parts of the world. To illustrate that, in North America, B. burgdorferi is the only pathogen that causes disease in humans, and the infection’s prevailing manifestations are Lyme arthritis and EM. At the same time, it occasionally leads to LNB in association with B. burgdorferi [5]. On the other hand, in Europe, five species have been shown to cause human disease: B. garinii, B. afzelii, B. burgdorferi sensu stricto, B. spielmanii, and B. bavariensis. Borrelia afzelii is more commonly associated with EM, and B. garinii and B. bavariensis occur more frequently in LNB [6, 7]. The neurotropism of Borrelia is, therefore, specific to particular species, and disparities between representatives of the species exist [8].

The aim of our narrative review is twofold: firstly, to present the known pathogenetic mechanisms of LNB and their possible relationship to the development of dementia syndrome in LD; secondly, to compare the different types of primary dementia syndromes with those of LNB.

Review

Pathogenesis of LNB

Borrelia expresses numerous molecules, such as outer surface protein A (OspA) and OspC, that are necessary for its development in ticks [9]. Both molecules are highly immunogenic, and after entering the blood circulation of the mammal host, Borrelia "hides'' them to avoid the immune response [9,10]. Further, it has been found that only OspA-negative Borrelia can infect mammals [11]. OspC is initially required to bind to the complement inhibitory protein Salp15 from the tick's saliva [12, 13]. In addition, the pathogen possesses a wide variety of mechanisms that enable evasion of the host’s immune system. Additionally, the complement-blocking proteins that the bacteria produce include the host complement regulatory protein CD59 (protectin), the factor H-binding outer surface protein E paralogs [14], and the complement regulatory-acquiring surface proteins (CRASPs) [9,15,16]. These particles increase interleukin (IL)-10 secretion in mononuclear cells [17]. Likewise, Borrelia can block opsonization by synthesizing soluble antigens that bind to antibodies [18]. Similarly, bacteria can bind to various proteins, such as decorin and fibronectin, which allow them to hide in immune-privileged tissues like the extracellular matrix [9, 19]

The entry of Borrelia into the central nervous system (CNS) needs to be better studied, although two main pathways have been suggested: circulatory and peripheral nerves [9]. Once in the CNS, Borrelia encounters monocytes, macrophages, and dendritic cells that synthesize proinflammatory cytokines (IL-6, IL-8, IL-12, IL-18, or interferon (IFN)-γ) and chemokines (CCL19, CCL21, CXCL12, and CXCL13) [20]. Chemokines attract B-cells and lead to B-cell infiltration [21]. In addition to B-cells, activated CD8+ and CD4+ T cells can also be detected [22]. Thus, it leads to lymphocytic pleocytosis, which can be observed in the cerebrospinal fluid (CSF) [21]. Non-human primates (NHPs) have been used in experimental studies to recreate aspects of the pathogenesis of LNB. According to observations supported by positive CSF cultures of B. burgdorferi and pleocytosis, LNB is linked to direct spirochetal invasion [23,24]. Another way in which B. burgdorferi infection can affect the nervous system is through molecular mimicry. This occurs when antibodies to B. burgdorferi flagellin are produced in the patient's body and then react with neural antigens [25]. Recent studies have explored the role of the B-cell-attracting chemokine CXCL13 as a diagnostic marker in patients with early LNB. It was elevated in nearly all of these patients before detecting anti-Borrelia antibodies. Furthermore, CXCL13 levels tend to decrease rapidly after the start of antibiotic therapy, which is not the case regarding the anti-Borrelia antibodies [26]. CXCL13 can also be detected in other manifestations of LD, such as borrelial lymphocytoma [27]. In some other neurologic manifestations of LD, the CXCL13 assay is negative, for example, in patients with Lyme encephalopathy [28]. It is, however, important to note that elevated CXCL13 in the CSF can also be a marker for noninfectious neurologic diseases such as aseptic meningitis [26].

Parthasarathy et al. (2023) [29] examined the significance of the fibroblast growth factor (FGF)/FGF receptor (FGFR) system in Borrelia-induced microglial neuroinflammation. It was found that the pathogen played an essential role in the pathogenesis of primary dementia syndromes and their complications. In some cases, this system may promote a pro-inflammatory response and, in others, an anti-inflammatory one. If this system excessively promotes pro-inflammatory responses, it could contribute to neurodegenerative disorders such as Alzheimer’s disease. Understanding its role may have therapeutic use in developing drugs that target it. FGFR1 also contributes to inflammation mediated by non-viable B. burgdorferi[29]. 

Stages and manifestation

Lyme disease is generally classified as an early localized infection, an early disseminated infection, or a late disseminated infection [30]. Joint pain and fever are common symptoms in the first stage, which develop days to weeks after the initial tick bite [24]. In the phase of an early disseminated infection, 10%-15% of untreated patients can develop neurological disorders referred to as early LNB [31]. Such manifestations appear four to six weeks postexposure and present as radiculopathy [31], lymphocytic meningitis, mononeuritis multiplex, and otolaryngological symptoms (tinnitus, vertigo, and hearing loss) [1]. Lyme meningoradiculitis (Bannwarth's syndrome), with intense pain, frequent paresis, and headaches, is the most widespread form of the disease [32]. In the USA, the most common symptom of early disseminated neuroborreliosis is facial palsy, in association with pleocytosis and other CSF abnormalities [33]. Lyme meningitis in children is also relatively frequent [34].

In the late disseminated infection stage, neurological manifestations are associated with Lyme encephalopathy [35], a syndrome involving cognitive difficulties as well as memory loss and personality changes, which is a topic of controversy in the USA [5]. In Europe, cases of late disseminated LNB have been reported with both peripheral manifestations (mononeuropathy, radiculopathy) and central nervous system involvement (cerebral vasculitis, encephalomyelitis with spastic syndrome) [36]. The cases of predominantly sensory peripheral neuropathy with paresthesia in Europe are associated with ACA [37]. Disseminated encephalomyelitis most often manifests itself with spastic syndrome and symptoms of fatigue and gait disturbances similar to those in multiple sclerosis [37]. Dementia-like syndromes and cognitive disturbances in the USA have been observed in the context of the aforementioned encephalopathy and as a post-treatment LD syndrome [38]. In Europe, they are regarded as a rare complication of cerebral vasculitis-like involvement and also in the context of post-treatment Lyme disease syndrome (PTLDS) [37,39].

Lyme neuroborreliosis-associated dementia-like syndrome

Dementia syndrome in general is an acquired and progressive loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational function [40]. Dementia is an umbrella syndrome associated with memory impairment and loss, cognitive disturbances, and personality changes to such an extent that they interfere with daily life. Symptoms can be related to Alzheimer’s disease, frontotemporal dementia (FTD), vascular dementia (VD), Lewy body dementia (LDB), Huntington’s disease, mixed dementia syndromes, and others. The most common clinical form of the disease is “mixed dementia, usually a combination of a common age-related neurodegenerative disease, most often Alzheimer’s disease and VD [40]. On the other hand, dementia-like syndrome can be an extremely rare manifestation of LNB, and the current understanding of its pathogenesis, manifestations, and treatment is limited. Some studies have concluded that LNB patients did not have increased long-term risks of dementia, Alzheimer’s disease, Parkinson’s disease, motor neuron diseases, epilepsy, or Guillain-Barré, but might have an increased short-term risk of epilepsy and Guillain-Barré syndrome [41]. 

Nevertheless, dementia-like syndromes have been occasionally reported in the last few years, and our article aims to summarize the similarities as well as differences between dementia associated with LNB and primary neurodegenerative dementia syndromes such as those mentioned above.

In order to associate existing dementia with a previous B. burgdorgeri infection, clinicians must execute a serology evaluation test and also immunology for intrathecal antibody production. A positive intrathecal anti-Borrelia antibody index (AI) is necessary to support the diagnosis. Since LNB is an inflammatory disease of the CNS, it is characterized by the phenomenon of lymphocytic pleocytosis in the CSF, an increased number of leukocytes at the expense of lymphocytes and plasma cells, along with an increased protein level (Table 1) [42].

Table 1 Diagnosis of Lyme neuroborreliosis (LNB) based on the European Federation of Neurological Societies (EFNS) guidelines

For a diagnosis of definite Lyme neuroborreliosis, all three criteria must be met; for a diagnosis of possible Lyme neuroborreliosis, at least two of the three criteria must be met.

Criteria	Definite neuroborreliosis	Possible neuroborreliosis	
Intrathecal antibody production	+	+	+	-	
Cerebrospinal fluid pleocytosis	+	+	-	+	
Neurological symptoms suggestive of LNB without other obvious reasons	+	-	+	+	

A study in Strasbourg involved 20 patients exhibiting dementia syndrome and a positive AI. A ceftriaxone dosage of 2 g/daily was administered to all of them, and they were divided into two groups. Group 1 (N = 7) exhibited a stable or improved course of their dementia syndrome. Group 2 (N = 13) demonstrated a deterioration during treatment, and all participants from this group showed evidence of an underlying primary dementia syndrome such as Alzheimer’s disease, Lewy body disease, frontotemporal dementia, and vascular dementia. They concluded that both pure Lyme dementia and primary neurodegenerative dementia associated with positive AI exist; fortunately, Lyme dementia without other neurocognitive comorbidities has a better outcome after the antibiotic treatment [39].

Post-treatment Lyme disease syndrome

In recent years, the subject matter of PTLDS has been excessively studied, and literature reports have significantly increased [1,38,43]. Post-treatment Lyme disease syndrome refers to a long-term condition where individuals who have been successfully treated for Lyme disease continue to experience memory loss, language difficulties, and impaired mental processing [44]. It is believed that both the bacterium itself and the persistence of bacterial debris trigger an immune response to the infection [28]. Although there is general consensus that PTLDS is a syndrome following treated LNB, there is still controversy surrounding its treatment with long-term antibiotic therapy [45]. The evidence provided in the medical literature so far is unanimous in confirming that long-lasting antibacterial therapy does not benefit patients with PTLDS [28].

Lyme neuroborreliosis and other types of dementia

Alzheimer’s disease is the main cause of dementia and one of the great healthcare challenges of the 21st century. It presents with typical (memory impairment and executive dysfunction interfering with daily-life activities) and atypical manifestations (language, visual, practical, or executive problems before and more pronounced than memory deficits) [46]. In a case report from 2023, a 75-year-old patient was first admitted to an Alzheimer’s care unit due to psychiatric disturbances and aggressive behavior. The patient underwent multiple different examinations and diagnostic tests where meningitis, limbic encephalitis, and syphilis were excluded (Creutzfeldt-Jakob disease was also a hypothesis). The patient scored 22/30, 3/5, 35/100, and 7/28 on the Mini-Mental State Exam (MMSE), Clinical Dementia Rating (CDR®), Barthel index, and Tinetti scale, respectively. The positive serology tests for Borrelia confirmed the diagnosis, as the patient also had arthritis and reported a tick bite six months prior (EM was not present). After a complete 21-day course of antibiotic treatment with intravenous ceftriaxone (2 g/daily), followed by oral doxycycline (200 mg/daily for seven days), his neurological symptoms improved, and his newly assessed scores were 29/30, 2/5, 62/100, and 25/28 [47].

Kristoferitsch et al. [37] present a series of 10 clinical cases where the onset of dementia-like syndrome manifests itself faster compared to primary dementia syndrome. Patient number 10, a 76-year-old female, was admitted with symptoms of progressing cognitive decline, weight loss, gait disturbance, and tremors over the last 12 months. Since the patient also suffered from mild hypertension, vascular encephalopathy was thought to be the most likely cause of the decline, but this was excluded. Her significant weight loss (20 kg/year) was more indicative of LD in contrast to Alzheimer’s disease (mean weight loss 0.9 kg/year). She was diagnosed with LNB when further CSF examinations disclosed a highly elevated AI. The patient was treated with 2 g of ceftriaxone daily for three weeks, and the symptoms rapidly improved. 

Frontotemporal dementia is common in patients younger than 65 years. It is characterized by frontotemporal atrophy on diagnostic imaging and is classified into the following subtypes: behavioral-variant frontotemporal dementia, nonfluent variant primary progressive aphasia, and semantic-variant primary progressive aphasia [48]. Depending on the type of FTD, we have different types of symptoms, consisting of behavioral change, including inappropriate ones, apathy, aphasia, language deficit, etc. [49]. Batistta et al. [50] describe a case of a 61-year-old patient diagnosed with borreliosis at the age of 57 years, treated with doxycycline 200 mg/day for 21 days. After a few weeks, depressive episodes and apathy appeared, so she started treatment at another center with doxycycline 200 mg/day for 14 days. After the course of treatment, anxiety and panic attacks appeared, and depressive episodes worsened. Treatment with benzodiazepine and antidepressant therapy was started; it did not affect the symptoms; socially inappropriate behavior, excessive smoking, and food intake appeared. Cerebrospinal fluid tests were performed, of which IgM and IgG were negative; the polymerase chain reaction (PCR) test was negative for the presence of B. burgdorferi. Both MRI and fludeoxyglucose-18-positron emission tomography (FGD-PET) were performed with signs characteristic of FTD. 

Dementia with Lewy bodies is the third most common dementia after Alzheimer's disease and VD. It has an earlier onset than Alzheimer's dementia and is often associated with visual hallucinations, attention deficit, rapid progression, and extrapyramidal symptomatology [51]. Gadilka et al. [52] present a case of a 69-year-old female patient who was diagnosed with LD at the age of 54 and treated for 10 days with doxycycline 200 mg/day until her condition improved. After four years, cognitive changes as well as photophobia and paresthesias appeared. Sputum tests were performed, which showed no pleocytosis and no intrathecal production of antibodies to Borrelia. Given the early motor disturbances, rapid eye movement (REM), behavioral disorder, paranoia, and personality changes, the diagnosis of LDB was made, but no readily available convincing evidence of a link between LNB and LDB is presented [53].

Another common type of dementia is VD (about 15% of cases), which has similar symptoms to Alzheimer's dementia and has several subtypes: multi-infarct, strategic infarct, hemorrhagic, hereditary, hypoperfusion, and small vessel dementia [54]. One of the risk factors for developing VD is a history of stroke, with 15%-30% of the people surviving stroke developing dementia over time [55]. No cases of VD resulting from LNB have been described. However, cases of stroke resulting from acute LNB have been reported, with a putative mechanism being the development of small vessel vasculitis due to perivascular and vascular infiltration with lymphocytes (Table 2) [56].

Table 2 Clinical characteristics of different types of dementias

Dementia type	Medical history	Main clinical features	Neurological status	Diagnostic imaging	Cerebrospinal fluid (CSF) findings	
Alzheimer’s disease (AD)	Gradual, insidious onset	Memory and cognition impairment, loss of independence in daily activities	Initially normal	Global atrophy (especially the hippocampus and parahippocampal gyrus)	Elevated tau, p-tau, and beta-amyloid 42 (Aß42)	
Frontotemporal dementia	Behavioral, emotional, and personality changes, aphasia	Expressive aphasia, apathy, euphoria, depression, disinhibition	Vertical gaze palsy, axial rigidity, dystonia, alien hand	Atrophy of frontal, insular, and/or temporal lobes; spares posterior lobe	Higher levels of Aß42, and lower t-tau/Aß42 and p-tau/Aß42 values compared with AD	
Vascular dementia	History of transient ischemic attack/stroke, vascular risk factors, hemiparesis, urinary incontinence	Cognitive slowing could spare memory, apathy, or depression	Motor slowing, spasticity	Lacunar/non-lacunar infarction, white matter lesions	Elevated interleukin-6 and C-reactive protein, elevated levels of lipocalin 2 (LCN2) compared to other dementias	
Lewy body dementia	Visual hallucinations, rapid eye movement (REM), sleep disorders, parkinsonism	Extrapyramidal signs such as Parkinsonism which includes rigidity, tremors, gait disturbance, autonomous nervous system symptoms	Parkinsonism	Posterior parietal atrophy occipital hypometabolism on fluorodeoxyglucose-positron emission tomography (FDG-PET), hippocampi larger than in AD	Elevated levels of Lewy bodies (α-synuclein), tau protein, and other proteins (ubiquitin, neurofilament protein), amyloid deposits	
Lyme neuroborreliosis-associated dementia	Tick bite history, fever, joint pain, erythema migrans	Radiculopathy, lymphocytic meningitis, mononeuritis, multiplex otolaryngological symptoms (tinnitus, vertigo)	Bannwarth’s syndrome, sensory peripheral neuropathy with paresthesia associated with acrodermatitis chronica atrophicans Lyme encephalitis	An MRI can show areas of inflammation, with increased signal on T2 and fluid-attenuated inversion recovery (FLAIR) imaging	Lymphocytosis, monocytosis, or both intrathecal production of anti-Borrelia antibodies	

We have only two large population-based studies, one in the USA, which found no epidemiological association between the occurrence of Alzheimer's disease and LNB [57] (however, LNB is more common in the European population), and another in Denmark, which found no risk of developing dementia syndrome in patients with LNB [41]. However, the risk was assessed for a period of one year, with patients on treatment during this time.

A differential diagnosis of the various forms of dementias, including Lewy body disease, is a challenging and multi-faceted process. It requires consideration of the patient's overall physical condition and the findings of a comprehensive neurological examination, as well as the results of advanced diagnostic techniques. Investigations may include imaging (e.g., atrophy of the cerebral cortex or other parts of the brain, or traces of inflammation) or a CSF examination (to look for characteristic proteins, such as tau, beta-amyloid 42, IL-6, α-synuclein, and Ab).

Conclusions

Current knowledge of the dementia-like syndrome caused by LNB is still quite limited. Only a few cases have been described in the medical literature, and not many dedicated studies have been conducted on this subject. We suggest that this may be due to several challenging factors: the frequent confusion between LNB and other neurological diseases, the substantial difficulty in the differential diagnosis of various dementia syndromes, and the selection of appropriate patients/cohorts of patients, as dementia syndrome usually develops slowly, suggesting the involvement of patients who may have already been in the initial stages of primary dementia syndrome. Therefore, the topic of dementia syndrome and LNB is a challenging one, and more control studies are needed. Attention in the diagnosis of a secondary dementia-like syndrome associated with LNB should be directed to generalized somatic manifestations (fever) that are usually absent in primary dementia syndromes, possibly a CSF examination for evidence of intrathecal antibody production, especially if the patient has previously visited a region endemic for LD. Proper differentiation with other neurological or infectious diseases is essential to providing our patients with the best possible care.

Disclosures

Author Contributions

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Dzhaner H. Bashchobanov, Eva Stamatova, Radina Andonova, Elena Dragusheva, Veronika Gadzhovska, Georgi Popov

Acquisition, analysis, or interpretation of data:  Dzhaner H. Bashchobanov, Radina Andonova, Elena Dragusheva, Veronika Gadzhovska, Georgi Popov

Drafting of the manuscript:  Dzhaner H. Bashchobanov, Eva Stamatova, Radina Andonova, Elena Dragusheva, Veronika Gadzhovska, Georgi Popov

Critical review of the manuscript for important intellectual content:  Dzhaner H. Bashchobanov, Eva Stamatova, Radina Andonova, Elena Dragusheva, Georgi Popov

Supervision:  Dzhaner H. Bashchobanov, Radina Andonova, Georgi Popov
==== Refs
References

1 Lyme borreliosis Lancet Stanek G Wormser GP Gray J Strle F 461 473 4 2012
2 Lyme disease-a tick-borne spirochetosis? Science Burgdorfer W Barbour AG Hayes SF Benach JL Grunwaldt E Davis JP 1317 1319 216 1982 7043737
3 Discovery of the Lyme disease agent mBio Barbour AG Benach JL 0 19 10 2019
4 Lyme borreliosis and skin Indian J Dermatol Vasudevan B Chatterjee M 167 174 58 2013 23723463
5 Comparison of Lyme disease in the United States and Europe Emerg Infect Dis Marques AR Strle F Wormser GP 2017 2024 27 2021 34286689
6 Borrelia bavariensis sp. nov. is widely distributed in Europe and Asia Int J Syst Evol Microbiol Margos G Wilske B Sing A 4284 4288 63 2013 23838444
7 Lyme disease: diagnosis and management Pract Neurol Ross Russell AL Dryden MS Pinto AA Lovett JK 455 464 18 2018 30282764
8 Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis Clin Infect Dis van Dam AP Kuiper H Vos K 708 717 17 1993 7903558
9 The pathogenesis of lyme neuroborreliosis: from infection to inflammation Mol Med Rupprecht TA Koedel U Fingerle V Pfister HW 205 212 14 2008 18097481
10 Antigenic variation with a twist-the Borrelia story Mol Microbiol Norris SJ 1319 1322 60 2006 16796669
11 Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks Proc Natl Acad Sci U S A Ohnishi J Piesman J de Silva AM 670 675 98 2001 11209063
12 OspC facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary glands J Clin Invest Pal U Yang X Chen M 220 230 113 2004 14722614
13 Complementation of a Borrelia afzelii OspC mutant highlights the crucial role of OspC for dissemination of Borrelia afzelii in Ixodes ricinus Int J Med Microbiol Fingerle V Goettner G Gern L Wilske B Schulte-Spechtel U 97 107 297 2007 17267282
14 Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs J Immunol Alitalo A Meri T Lankinen H 3847 3853 169 2002 12244181
15 Immune evasion of Borrelia burgdorferi: insufficient killing of the pathogens by complement and antibody Int J Med Microbiol Kraiczy P Skerka C Kirschfink M Zipfel PF Brade V 141 146 291 2002 12141738
16 Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule J Immunol Pausa M Pellis V Cinco M 3214 3222 15 2003 http://www.jimmunol.org/content/170/6/3214
17 Borrelia burgdorferi stimulates the production of interleukin-10 in peripheral blood mononuclear cells from uninfected humans and rhesus monkeys Infect Immun Giambartolomei GH Dennis VA Philipp MT 2691 2697 66 1998 9596735
18 Borrelia burgdorferi-specific immune complexes in acute Lyme disease JAMA Schutzer SE Coyle PK Reid P Holland B 1942 1946 282 1999 10580460
19 Hidden in plain sight: Borrelia burgdorferi and the extracellular matrix Trends Microbiol Cabello FC Godfrey HP Newman SA 350 354 15 2007 17600717
20 Increased expression of the Th1-inducing cytokines interleukin-12 and interleukin-18 in cerebrospinal fluid but not in sera from patients with Lyme neuroborreliosis J Neuroimmunol Grusell M Widhe M Ekerfelt C 173 178 131 2002 12458049
21 Cerebrospinal fluid interleukins, immunoglobulins, and fibronectin in neuroborreliosis Arch Neurol Weller M Stevens A Sommer N Wiethölter H Dichgans J 837 841 48 1991 1898258
22 Clonal accumulation of activated CD8+ T cells in the central nervous system during the early phase of neuroborreliosis J Infect Dis Jacobsen M Zhou D Cepok S 963 973 187 2003 12660943
23 Inoculation of nonhuman primates with the N40 strain of Borrelia burgdorferi leads to a model of Lyme neuroborreliosis faithful to the human disease Neurology Pachner AR Delaney E O'Neill T Major E 165 172 45 1995 7824109
24 Lyme neuroborreliosis: clinical outcomes, controversy, pathogenesis, and polymicrobial infections Ann Neurol Garcia-Monco JC Benach JL 21 31 85 2019 30536421
25 Cross-reactivity between Borrelia burgdorferi flagellin and a human axonal 64,000 molecular weight protein J Infect Dis Sigal LH 1372 1378 167 1993 8501326
26 Lyme neuroborreliosis-epidemiology, diagnosis and management Nat Rev Neurol Koedel U Fingerle V Pfister HW 446 456 11 2015 26215621
27 Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma Infect Immun Müllegger RR Means TK Shin JJ 4621 4628 75 2007 17606602
28 Neuroimmunomodulators in neuroborreliosis and Lyme encephalopathy Clin Infect Dis Eckman EA Pacheco-Quinto J Herdt AR Halperin JJ 80 88 67 2018 29340592
29 The FGF/FGFR system in the microglial neuroinflammation with Borrelia burgdorferi: likely intersectionality with other neurological conditions J Neuroinflammation Parthasarathy G Pattison MB Midkiff CC 10 20 2023 36650549
30 Lyme disease in humans Curr Issues Mol Biol Radolf JD Strle K Lemieux JE Strle F 333 384 42 2021 33303701
31 Progressive Borrelia encephalomyelitis. Chronic manifestation of erythema chronicum migrans disease of the nervous system (Article in German) Dtsch Med Wochenschr Ackermann R Gollmer E Rehse-Küpper B 1039 1042 110 1985 4006760
32 The neuropsychiatric manifestations of Lyme borreliosis Psychiatr Q Fallon BA Nields JA Burrascano JJ Liegner K DelBene D Liebowitz MR 95 117 63 1992 1438607
33 Lyme neuroborreliosis Continuum (Minneap Minn) Marques AR 1729 1744 21 2015 26633786
34 Neurologic manifestations in children with North American Lyme disease Neurology Belman AL Iyer M Coyle PK Dattwyler R 2609 2614 43 1993 8255465
35 Chronic neurologic manifestations of Lyme disease N Engl J Med Logigian EL Kaplan RF Steere AC 1438 1444 323 1990 2172819
36 Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients Int J Med Microbiol Pfister HW Rupprecht TA 11 16 296 Suppl 40 2006
37 Secondary dementia due to Lyme neuroborreliosis Wien Klin Wochenschr Kristoferitsch W Aboulenein-Djamshidian F Jecel J Rauschka H Rainer M Stanek G Fischer P 468 478 130 2018 30046879
38 Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial Neurology Krupp LB Hyman LG Grimson R 1923 1930 60 2003 12821734
39 Lyme neuroborreliosis and dementia J Alzheimers Dis Blanc F Philippi N Cretin B 1087 1093 41 2014 24762944
40 Diagnosis and management of dementia: review JAMA Arvanitakis Z Shah RC Bennett DA 1589 1599 322 2019 31638686
41 Risk of neurological disorders in patients with European Lyme neuroborreliosis: a nationwide, population-based cohort study Clin Infect Dis Haahr R Tetens MM Dessau RB 1511 1516 71 2020 31598647
42 EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis Eur J Neurol Mygland A Ljøstad U Fingerle V Rupprecht T Schmutzhard E Steiner I 8 4 8-16, e1-4 17 2010 19930447
43 Long-term outcomes of persons with Lyme disease JAMA Seltzer EG Gerber MA Cartter ML Freudigman K Shapiro ED 609 616 283 2000 10665700
44 Subjective symptoms after treatment of early Lyme disease Am J Med Cerar D Cerar T Ruzić-Sabljić E Wormser GP Strle F 79 86 123 2010 20102996
45 Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease N Engl J Med Klempner MS Hu LT Evans J 85 92 345 2001 11450676
46 Alzheimer's disease Lancet Scheltens P De Strooper B Kivipelto M 1577 1590 397 2021 33667416
47 A case of reversible dementia? Dementia vs delirium in Lyme disease Ann Geriatr Med Res Sanchini C Papia C Cutaia C Poloni TE Cesari M 80 82 27 2023 36740841
48 Frontotemporal dementia Lancet Bang J Spina S Miller BL 1672 1682 386 2015 26595641
49 Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia Brain Rascovsky K Hodges JR Knopman D 2456 2477 134 2011 21810890
50 Frontotemporal dementia misdiagnosed for post-treatment Lyme disease syndrome or vice versa? A Treviso dementia (TREDEM) registry case report J Alzheimers Dis Di Battista ME Dell'Acqua C Baroni L Fenoglio C Galimberti D Gallucci M 445 451 66 2018 30282363
51 Neuropathology of Lewy body disease: clinicopathological crosstalk between typical and atypical cases Neuropathology Kon T Tomiyama M Wakabayashi K 30 39 40 2020 31498507
52 Detecting Borrelia spirochetes: a case study with validation among autopsy specimens Front Neurol Gadila SK Rosoklija G Dwork AJ Fallon BA Embers ME 628045 12 2021 34040573
53 Lack of convincing evidence that Borrelia burgdorferi infection causes either Alzheimer disease or Lewy body dementia Clin Infect Dis Wormser GP Marques A Pavia CS Schwartz I Feder HM Pachner AR 342 346 75 2022 34849631
54 Vascular dementia Lancet O’Brien JT Thomas A 1698 1706 24 2015
55 Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis Lancet Neurol Pendlebury ST Rothwell PM 1006 1018 8 2009 19782001
56 Lack of convincing evidence that Borrelia burgdorferi infection causes either Alzheimer disease or Lewy body dementia Brain Sci Akkurt BH Kraehling H Nacul NG 1388 13 2023 37891757
57 No geographic correlation between Lyme disease and death due to 4 neurodegenerative disorders, United States, 2001-2010 Emerg Infect Dis Forrester JD Kugeler KJ Perea AE Pastula DM Mead PS 2036 2039 21 2015 26488307
